Coreceptor Usage of Human Immunodeficiency Virus Type 2 Primary Isolates and Biological Clones Is Broad and Does Not Correlate with Their Syncytium-Inducing Capacities |
| |
| Authors: | Christophe Guillon Marchina E van der Ende Patrick H M Boers Rob A Gruters Martin Schutten and Albert D M E Osterhaus |
| |
| Affiliation: | Institute of Virology, Erasmus University Rotterdam,1. and Department of Internal Medicine, University Hospital Dijkzigt,2. Rotterdam, The Netherlands, and UMR 103 CNRS/bioMérieux, Ecole Normale Supérieure de Lyon, Lyon, France3. |
| |
| Abstract: | Entry of human immunodeficiency virus type 1 (HIV-1) into target cells is mediated by binding of the surface envelope glycoprotein to the CD4 molecule. Interaction of the resulting CD4-glycoprotein complex with α- or β-chemokine receptors, depending on the biological phenotype of the virus, then initiates the fusion process. Here, we show that primary HIV-2 isolates and biological clones, in contrast to those of HIV-1, may use a broad range of coreceptors, including CCR-1, CCR-3, CCR-5, and CXCR-4. The syncytium-inducing capacity of these viruses did not correlate with the ability to infect via CXCR-4 or any other coreceptor. One cell-free passage of the intermediate isolates in mitogen-stimulated, CD8+ cell-depleted peripheral blood mononuclear cells resulted in the outgrowth of variants with CCR-5 only, whereas the coreceptor usage of late and early isolates did not change. Since HIV-2 is less pathogenic in vivo than HIV-1, these data suggest that HIV pathogenicity in vivo is not directly related to the spectrum of coreceptors used in in vitro systems. |
| |
| Keywords: | |
|
|
